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ABSTRACT
Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients
who may develop severe symptoms, the process called ‘viral sepsis’ seems to be a crucial mechanism. In those cases, the
HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome
of four HD patients with severe COVID-19 treated with SeraphVR 100 haemoperfusion (HP) device. Three of the four cases
presented a good clinical response after HP. In conclusion, the treatment with SeraphVR 100 device may be a simultaneous
treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2.
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BACKGROUND
In-centre haemodialysis (HD) patients show a major coronavi-
rus disease 2019 (COVID-19) incidence with a high mortality
rate [1]. Among 848 prevalent HD patients in our health area,
the incidence of COVID-19 was 14.3% with a mortality rate of
23%. In patients who develop severe symptoms, the process
called ‘viral sepsis’ seems to be a crucial mechanism [2, 3]. Up to
now, the management of COVID-19 infection is mainly based
on supportive therapy [4]. However, the HD procedure provides
an excellent tool to explore the benefit of some extracorporeal
therapies aimed to reduce ‘viral sepsis’.
The Extracorporeal device SeraphVR 100 MicrobindVR Affinity
Blood produced by ExThera Medical (Martinez, CA, USA) is a
haemoperfusion (HP) device approved by the US and European
agencies for the reduction of some bacterial and viral patho-
gens. Moreover, on 17 April 2020, the US Food and Drug
Administration granted COVID-19 emergency use authoriza-
tions for the SeraphVR 100. This device has ultrahigh molecular
weight polyethylene beads with end point-attached heparin [5].
Herein we describe the first four cases of HD patients with se-
vere COVID-19 treated with SeraphVR 100 HP.
METHODS
The procedure consisted of two sessions of HP with SeraphVR 100
in parallel with standard HD performed in two consecutive
days. The SeraphVR 100 was placed pre-dialyzer. Blood samples
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were taken to admission, at the start and the end of each HP
and subsequent days of treatment until the patients were dis-
charged. Patients selected for treatment were not candidates for
intensive therapy.
CASE REPORTS
Table 1 summarizes the main characteristics of the four
patients treated with HP. All patients were very old, had some
comorbidities and criteria of bad prognosis and severe pulmo-
nary involvement. The HP was started between Days 2 and 13
after the symptomatology onset. All patients but Patient 2
showed favourable outcome and were discharged. In Patient 2,
the HP was incompletely performed because of hemodynamic
intolerance. Table 1 shows the evolution of some inflammatory
and coagulation parameters during the HP procedure.
Interestingly, comparing pre-HP with post-HP, we did not ob-
serve a significant reduction in interleukin-6, ferritin and D-di-
mer. The decrease of these inflammatory parameters appeared
after the two-session HP protocol was completed in responder
patients. The second peak increase of ferritin in Patient 4 was
related to secondary bacterial pneumonia that was successfully
treated with antibiotics.
DISCUSSION
COVID-19 direct viral attack on lung epithelial cells, lung capil-
lary endothelial cells, vascular endothelial cells with high levels
of ACE2 and T lymphocytes [2, 3] may account for the severe in-
flammatory response, microcirculation dysfunction and pro-
thrombotic state observed in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Theoretically, the reduction of viral
load and/or some inflammatory mediators may alleviate the
course of the disease. SeraphVR 100 is an HP device that mimics
the endothelial cell glycocalyx that has an anti-thrombogenic,
anti-inflammatory and pathogen immobilization effect by se-
lective adsorption. Four hours in vitro perfusion provides >99%
reduction of HSV-1, HSV-2, Ebola, Zika, CMV and adenoviruses
[5]. Also, COVID-19 and other coronaviruses bind to heparin and
so it seems feasible that COVID-19 will bind to SeraphVR 100
sorbent.
Patients on HD are particularly susceptible to infection by
several mechanisms including deficient immune response. On
the contrary, HD patients have an impaired glycocalyx barrier
and sustained endothelial cell activation as mechanisms in-
volved in viral shedding. Thus, increased viral shedding in com-
bination with a deficient immune response may put HD
Table 1. Clinical features, laboratory and HP parameters
Patient 1 Patient 2 Patient 3 Patient 4
Sex Male Male Female Male
Age (years) 86 87 87 81











LDH (U/L) 567a/545b 328a/303b 305a/308b 224a/259b
RCP (mg/L) 215a/174b 19.5a/14.6b 9.4a/7.4b 45.9a/58.4b
Ferritin (mg/L) 3235a/3871b 1677a/1501b 981a/1287b 587a/685b
IL-6 (ng/L) 123a/29b 10.4a/11.7b 56.6a/68.2b 28.4a/41.2b
D-dimer (mg/L) 537a/548b 1197a/1102b 490a/385b 337a/405b
Post-HP laboratory analysis
LDH (U/L) 635a/635b 335a/335b 266a/327b 239a/247b
RCP (mg/L) 239a/191b 18.9a/14.5b 7.7a/8.5b 54.6a/59.3b
Ferritin (mg/L) 4287a/5110b 1687a/1609b 1153a/1111b 580a/692b
IL-6 (ng/L) 162a/86b 21a/23.6b 58.8a/79.8b 48.7a/27.5b
D-dimer (mg/L) 1098a/902b 2427a/2870b 372a/499b 452a/498b
Discharge laboratory analysis
LDH (U/L) 340 335 259 241
RCP (mg/L) 13.4 14.5 3.1 53.1
Ferritin (mg/L) 1756 1609 593 1174
IL-6 (ng/L) 18.2 23.6 41.2 2.4
D-,dimer (mg/L) 484 2870 250 368
Arterial blood gases before to start first HP
FiO2 (%) 60 21 21 50
pO2 (mmHg) 150 64 45 74
pCO2 (mmHg) 33 31 38 33
PaO2/FiO2 ratio 250 304 214 148
HP and haemodialysis parameters
HP start (days after dis-
ease onset)
13 11 7 2
Blood flow (mL/min) 280a/300b 220a/200b 300a/300b 350a/350b
Time (min) 180a/240b 180a/150b 240a/240b 240a/240b
Conversion factor for U/L to ukat/L: 0.01667.
aFirst session HP.
bSecond session HP.
LDH, lactate dehydrogenase; RCP, reactive C protein; IL-6, interleukin 6; FiO2, inspired fraction of O2; pO2, O2 pressure; pCO2, CO2 pressure.
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patients on the worse clinical scenario. Actually, our patients
on HD with COVID-19 showed a mortality rate of 23%. However,
the dialysis session brings an excellent opportunity to perform
simultaneous HP. Blood passes over exclusive microbeads
coated with molecular receptor sites that mimic endothelial gly-
cocalyx before entering the haemodialyzer.
Herein, we reported the outcome of four HD patients with
severe COVID-19 treated with SeraphVR 100. All patients had cri-
teria of poor prognosis and were not suitable candidates to ICU
management. Interestingly, we observed a good clinical re-
sponse in three out of four cases. The Patient 2 had a clinical
worsening with intolerance to HP, dying 24 h after second HP.
As we did not observe reduction of inflammatory molecules
during the 4-h HP session, our hypothesis is that the HP benefi-
cial effect could be mainly related to the viral load reduction. In
this regard, it seems advisable to perform the HP earlier in the
course of the disease (in two out of the three responders HP was
performed in the first week).
In conclusion, HP with SeraphVR 100 during the first week after
the onset of the disease may be a simultaneous treatment to
improve the HD patients with severe SARS-CoV-2 although fur-
ther studies should be performed.
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